secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001104659-25-104004
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q3 net loss $59.1M; lead drug regulatory update delayed to Q1 2026
--------------------------------------------------------------------------------

- Net loss of $59.1M ($0.85 per share) vs $50.8M ($0.74) in Q3 2024; R&D expenses up 21% to $58.4M.
- Cash $648.3M (down from $879.5M at Dec 2024); additional $38.2M R&D tax credit received Oct 2025; runway into 2028.
- Dose selection for zelenectide pevedotin Duravelo-2 trial and potential approval pathway update expected Q1 2026.
- Strengthened Board with appointments of Charles Swanton, Roger Dansey, and Hervé Hoppenot.
- BT5528 and BT7480 combination data presentations pushed to H1 2026; initial BRC EphA2 human imaging data expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925104004/0001104659-25-104004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925104004/tm2529754d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-104004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer